Resources from the same session
2056 - IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)
Presenter: Peter Schmid
Session: Presidential Symposium 1
Resources:
Abstract
Slides
Webcast
Presidential Symposium 1 - Invited discussant
Presenter: Giuseppe Curigliano
Session: Presidential Symposium 1
Resources:
Slides
Webcast
5410 - Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2_) advanced breast cancer (ABC): Analyses from PALOMA-3
Presenter: Massimo Cristofanilli
Session: Presidential Symposium 1
Resources:
Abstract
Slides
Webcast
1048 - Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial
Presenter: Fabrice André
Session: Presidential Symposium 1
Resources:
Abstract
Slides
Webcast
3895 - Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer
Presenter: Zefei Jiang
Session: Presidential Symposium 1
Resources:
Abstract
Slides
Webcast
Presidential Symposium 1 - Invited discussant
Presenter: Rebecca Dent
Session: Presidential Symposium 1
Resources:
Slides